<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Severe combined immunodeficiency (SCID) with JAK3 deficiency</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Severe combined immunodeficiency (SCID) with JAK3 deficiency</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Severe combined immunodeficiency (SCID) with JAK3 deficiency</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fabio Candotti, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Luigi D Notarangelo, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer M Puck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Genetic pathogenic variants affecting the common gamma (gamma-c) chain of the interleukin (IL) 2 receptor and the associated downstream signaling enzyme Janus kinase 3 (JAK3) both result in a clinical presentation of T cell-negative, B cell-positive, natural killer (NK) cell-negative severe combined immunodeficiency (T-B+NK- SCID)  (<a class="graphic graphic_table graphicRef139920" href="/z/d/graphic/139920.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef77023" href="/z/d/graphic/77023.html" rel="external">figure 1</a>). In contrast to the X chromosome-linked gamma-c form of SCID that affects only males, SCID due to defects of the <em>JAK3</em> gene results in T-B+NK- SCID that is transmitted via an autosomal recessive mode of inheritance (MIM #600802) and affects males and females equally [<a href="#rid1">1-3</a>].</p><p>SCID due to JAK3 deficiency is increasingly identified in otherwise healthy infants by newborn screening with the T cell receptor excision circle (TREC) test [<a href="#rid4">4,5</a>] (see  <a class="medical medical_review" href="/z/d/html/16363.html" rel="external">"Newborn screening for inborn errors of immunity"</a>). However, in the past and in countries where SCID is not included in population-wide newborn screening panels, affected infants come to medical attention at a few months of age with infectious complications of SCID, including persistent, recurrent and increasingly severe bacterial, viral, and fungal infections; intractable diarrhea; thrush; and failure to thrive [<a href="#rid1">1-3,6-8</a>]. Patients may develop infections from opportunistic pathogens and live-attenuated vaccines. Graft-versus-host reaction from transplacentally acquired maternal T cells or donor allogeneic T cells from transfusions often increases the severity of the clinical phenotype. (See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview", section on 'Clinical manifestations'</a>.)</p><p>The pathogenesis, clinical features, diagnosis, and treatment of T-B+NK- SCID with JAK3 deficiency are presented in this topic review. An overview of the different forms of SCID can be found separately. (See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview"</a> and  <a class="medical medical_review" href="/z/d/html/3912.html" rel="external">"Severe combined immunodeficiency (SCID): Specific defects"</a>.)</p><p>Germline heterozygous gain-of-function mutations of the <em>JAK3</em> gene have been identified in patients with familial chronic lymphoproliferative disorder associated with immune dysregulation [<a href="#rid9">9</a>]. This rare condition is not discussed here.</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>SCID due to JAK3 deficiency is rare, accounting for only approximately 5 percent of all cases of SCID [<a href="#rid3">3,10,11</a>] and approximately 1 percent of all cases of immunodeficiency of known genetic origin [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Signal transduction by the hematopoietic cytokines, interleukin (IL) 2, IL-4, IL-7, IL-9, IL-15, and IL-21, is of critical importance for the development and function of the cells of the immune system [<a href="#rid13">13,14</a>]. Cellular receptors for all these cytokines share the common gamma chain (gamma-c) transmembrane receptor [<a href="#rid15">15-23</a>] that lacks intrinsic catalytic activity but mediates signal transduction via its physical association with other transmembrane cytokine receptor chains and an intracellular member of the Janus family of protein kinases, JAK3 [<a href="#rid20">20,24</a>].</p><p>Similar to pathogenic variants of gamma-c [<a href="#rid25">25,26</a>], JAK3 defects also cause a T-B+NK- SCID that is indistinguishable except for its autosomal recessive mode of inheritance (MIM #600802)  (<a class="graphic graphic_figure graphicRef77023" href="/z/d/graphic/77023.html" rel="external">figure 1</a>) [<a href="#rid1">1,2</a>], with females and males equally affected. Genetic pathogenic variants that impair the integrity of the gamma-c/JAK3 signaling pathway are characterized by a near total lack of circulating T lymphocytes and normal or increased number of B cells. Natural killer (NK) cells are usually severely reduced in numbers. In addition, JAK3 deficiency blocks development of innate lymphoid cells (ILCs) both in humans [<a href="#rid27">27</a>] and mice [<a href="#rid28">28</a>]. The negative effects of JAK3 deficiency on lymphoid development are recapitulated in JAK3-knockout zebrafish models [<a href="#rid29">29</a>].</p><p>SCID with JAK3 deficiency can be regarded as a failure of multiple cytokine-mediated signaling pathways, similar to X-linked severe combined immunodeficiency (X-SCID). In particular, impaired IL-7 signaling appears to be responsible for the pronounced defect in T cell development, while impaired IL-15 signaling [<a href="#rid30">30</a>] is most likely responsible for the characteristic lack of NK cells in patients with JAK3 deficiency. This was demonstrated in a patient with atypical JAK3 deficiency who had NK cells and functionally impaired CD4+ T cells that transduced IL-2, IL-4, IL-15, and IL-21 signals but failed to respond to IL-7 [<a href="#rid31">31</a>]. It is also corroborated by findings in IL-7 and IL-7 receptor alpha chain (IL-7R-alpha) knockout mice [<a href="#rid32">32,33</a>] and in humans affected with T-B+NK+ SCID due to IL-7R-alpha pathogenic variants [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/3912.html" rel="external">"Severe combined immunodeficiency (SCID): Specific defects", section on 'IL-7 receptor alpha chain (CD127) deficiency'</a>.)</p><p>In vitro studies of T cell differentiation with patient-derived induced pluripotent stem cells have shown that T cell development of JAK3-deficient cells is blocked at an early CD4<sup>-</sup> CD8<sup>-</sup> double-negative (DN) stage [<a href="#rid35">35</a>].</p><p>By comparison, B cell development is preserved up to the mature B cell stage, suggesting redundancy of the cytokines using the gamma-c/JAK3 axis for B cell lymphopoiesis in humans. However, intrinsic functions of B cells, including ability to undergo activation, proliferation, differentiation, and isotype switching, are impaired, resulting in the profound hypogammaglobulinemia and specific antibody deficiency characteristic of JAK3 deficiency [<a href="#rid1">1,2,6,36</a>].</p><p>In vitro studies with Epstein-Barr virus (EBV) immortalized lymphoblastoid B cell lines have shown impaired responses of JAK3-deficient B cells to IL-2 and IL-4 [<a href="#rid37">37,38</a>]. Response to IL-21 is critical for B germinal center formation and B cell differentiation and proliferation [<a href="#rid39">39,40</a>], and defective differentiation of B cells to plasmablasts has been reported in patients with JAK3 deficiency as a result of impaired IL-21-mediated signaling [<a href="#rid41">41,42</a>]. However, experience from bone marrow transplantation has indicated that JAK3-deficient B cells can in some cases mediate normal humoral immune responses after engraftment of human leukocyte antigen (HLA) identical allogeneic T cells [<a href="#rid43">43</a>], pointing to the lack of adequate T cell helper function as an important contributor to B cell dysfunction in JAK3 deficiency.</p><p class="headingAnchor" id="H4"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>The human <em>JAK3</em> gene maps to chromosome 19p12-13.1 [<a href="#rid44">44</a>], is composed of 23 exons [<a href="#rid45">45</a>], and contains an open reading frame of 3372 bp [<a href="#rid46">46</a>]. Many different types of pathogenic variants (deletions, insertions, missense, nonsense, and splice-site variants) affecting this locus have been described in patients with JAK3 deficiency, with no evidence for preferential hot spots, but reports of possible founder effects have been described [<a href="#rid3">3,47,48</a>]. Both "null" variants and defects compatible with residual expression of a mutated JAK3 protein have been observed. In all cases studied, however, these pathogenic variants interfere with normal cytokine signal transduction and result in severely reduced phosphorylation of the JAK3 molecule itself and of downstream proteins, such as the signal transducer and activator of transcription 5 (STAT5) [<a href="#rid2">2,3,6,7,37,38,43,49-52</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with SCID due to JAK3 deficiency are readily identified by newborn screening with the T cell receptor excision circle (TREC) assay routinely conducted in the US and in a growing number of countries worldwide. When not identified by population-based screening, JAK3-SCID typically presents at a few months of age with infectious complications that classically defined SCID in the pre-newborn screening era. These infants typically have recurrent or severe respiratory infections, intractable diarrhea, thrush, and failure to thrive [<a href="#rid1">1-3,6-8</a>]. Failure to recover from infections and coexisting infections with multiple pathogens are characteristic. Infections are frequently caused by opportunistic pathogens and become life threatening, a true pediatric medical emergency [<a href="#rid3">3,8,47</a>]. (See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview", section on 'Clinical manifestations'</a>.)</p><p>Infectious diarrhea caused by the attenuated live rotavirus vaccine is often present if infants have inadvertently received this vaccine, which is contraindicated in infants known to have immune defects [<a href="#rid53">53</a>]. Severe or fatal infection can be seen with other live-attenuated vaccines (oral polio, varicella, Bacillus Calmette-Guérin) as well. (See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview", section on 'Clinical manifestations'</a>.)</p><p>The immune system in infants with SCID is impaired in its capacity to reject foreign cells. Thus, these infants may present with graft-versus-host disease due to transplacentally acquired maternal T cells (or, if unirradiated transfusions have been given, unrelated-donor allogeneic T cells). The infiltrating foreign cells cause rashes, abdominal organomegaly, and tissue damage. In rare cases of hypomorphic pathogenic variant of <em>JAK3</em>, in which residual protein function is preserved, the disease may present as Omenn syndrome, with erythroderma rash, adenopathy, eosinophilia, elevated immunoglobulin E (IgE), and oligoclonal expansion of autologous T cells with poor diversity. (See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview", section on 'Detection of maternal T cell engraftment'</a> and  <a class="medical medical_review" href="/z/d/html/3950.html" rel="external">"T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'Omenn syndrome phenotype'</a>.)</p><p>Certain pathogenic variants of the <em>JAK3</em> gene can lead to a broad spectrum of clinical presentations, including milder immunodeficiency of later clinical onset or uncontrolled lymphocyte proliferation [<a href="#rid51">51</a>]. It is hypothesized that "leaky" <em>JAK3</em> variants compatible with the expression of low and variable levels of functional JAK3 protein are responsible for the differences in disease severity and the unique and almost paradoxical clinical features observed in some patients [<a href="#rid51">51</a>].</p><p>In one affected family, for example, compound heterozygote variants in the <em>JAK3</em> gene resulted in a severe lymphoproliferative disorder in an 8-year-old child, but his 18-year-old sibling with identical defects was nearly asymptomatic [<a href="#rid51">51</a>]. The genetic defects of these siblings were associated with low amounts of functional protein. In addition, somatic chimerism with presence of <em>JAK3</em> revertant T cells was reported in two affected siblings and appeared to modulate their clinical and immunologic phenotype, which evolved from combined immunodeficiency to predominant CD4<sup>+</sup> lymphopenia [<a href="#rid54">54</a>].</p><p>Skin granulomas have been reported in some patients with hypomorphic <em>JAK3</em> pathogenic variants [<a href="#rid55">55,56</a>]. Although no pathogens have been identified within these lesions, presence of the rubella virus vaccine strain has been demonstrated in granulomas of patients with other forms of combined immunodeficiency [<a href="#rid57">57</a>]. Chronic active Epstein-Barr virus (CAEBV) infection was reported as the presenting sign in an adolescent with hypomorphic JAK3 deficiency [<a href="#rid58">58</a>].</p><p>Thus, partial JAK3 defects may be the basis for the immunologic problems in patients with increased, but not overwhelming, susceptibility to infection and/or disorders of immune regulation who do not meet the typical phenotypic characteristics of SCID patients. Although most such patients are expected to have low numbers of TRECs that are identified in the neonatal period by TREC screening, further experience with these rare patients is required to define the disease presentation in the newborn screening era [<a href="#rid5">5</a>]. Indeed, immunologic investigations of patients with JAK3 deficiency identified by newborn screening may detect atypical findings that would only result in clinical manifestations in the posttransplant period [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H6"><span class="h1">LABORATORY FINDINGS</span><span class="headingEndMark"> — </span>Lymphopenia is a common, although not universal, laboratory finding in patients with T-B+NK- SCID due to JAK3 deficiency since B cells may be elevated in numbers, masking the lack of T and natural killer (NK) cells. However, CD3 T cells and, in particular, numbers of CD3/CD4- and CD3/CD8-positive T cells that express the CD45RA naïve marker are profoundly low. Flow cytometry analysis of lymphocyte subsets shows low to undetectable numbers of CD3 T cells and NK cells (&lt;50 NK cells/microL and &lt;1 percent of total lymphocytes), while B cell numbers are normal or increased [<a href="#rid6">6,8,47</a>]. Development of other types of innate lymphoid cells (ILCs), with the possible exception of ILC type 1 (ILC1), is also compromised in patients with SCID due to <em>JAK3</em> or interleukin 2 receptor gamma (<em>IL2RG</em>; common gamma [gamma-c] chain) pathogenic variants, although this deficiency may not contribute to increase susceptibility to infections [<a href="#rid27">27</a>]. Studies in Jak3-mutated mice have shown that JAK3 deficiency results in a differentiation block of bone marrow ILC precursors [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview", section on 'Laboratory abnormalities'</a>.)</p><p>Immunoglobulin M (IgM) and immunoglobulin A (IgA) levels are markedly decreased despite the presence of B cells. Immunoglobulin G (IgG) acquired transplacentally during the last seven weeks of pregnancy is usually present initially and declines postnatally, and antibody responses are not elicited following immunization. The severe reduction in the number of T and NK cells is associated with a lack of in vitro proliferation to mitogens such as phytohemagglutinin (PHA) and of NK in vitro cytotoxic activity, respectively [<a href="#rid3">3,8,36,47</a>].</p><p class="headingAnchor" id="H4140793"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Only tests specific for JAK3 deficiency will be discussed here. The diagnosis of SCID, including newborn screening for SCID based on enumeration of T cell receptor excision circles (TRECs), is discussed in detail separately  (<a class="graphic graphic_table graphicRef67948" href="/z/d/graphic/67948.html" rel="external">table 2</a> and <a class="graphic graphic_algorithm graphicRef89448" href="/z/d/graphic/89448.html" rel="external">algorithm 1</a>). Neonatal screening identifies JAK3 deficiency in the first weeks of life, before appearance of clinical symptoms [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/16363.html" rel="external">"Newborn screening for inborn errors of immunity", section on 'Screening for SCID and other T cell defects'</a>.)</p><p>The genes that should be considered for sequencing in a patient with T-B+NK- SCID are <em>IL2RG</em>, encoding for the common gamma chain of the interleukin (IL) 2 receptor (gamma-c), in males and <em>JAK3</em> in both males and females  (<a class="graphic graphic_table graphicRef139920" href="/z/d/graphic/139920.html" rel="external">table 1</a>). X-linked severe combined immunodeficiency (X-SCID), caused by pathogenic variants of the <em>IL2RG</em> gene, encoding for gamma-c, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3927.html" rel="external">"X-linked severe combined immunodeficiency (X-SCID)"</a>.)</p><p>A definitive diagnosis of JAK3 deficiency requires demonstration of pathogenic variants of the <em>JAK3</em> gene and/or biochemical analysis revealing defective <em>JAK3</em> expression and/or function in patient lymphocytes. Biochemical studies (Western blot analysis of <em>JAK3</em> expression, assessment of JAK3 and/or signal transducer and activator of transcription 5 [STAT5] phosphorylation in response to cytokine stimulation) are usually performed on lymphoblastoid B cell lines obtained from affected patients after Epstein-Barr virus (EBV) mediated immortalization because only severely reduced numbers of T cells are available from lymphopenic infants, and they may be of maternal origin [<a href="#rid3">3,6,7,43,49-51</a>].</p><p>Preparing B cell lines for performing biochemical assays generally requires several weeks, during which diagnosis by gene sequencing can be performed. Screening assays based upon single-strand conformation polymorphisms (SSCP) techniques were formerly performed [<a href="#rid45">45</a>] but are rarely done now that rapid gene sequencing is available in most settings. In rare cases, deep intronic variants that create novel cryptic splice sites may also cause the disease, indicating the need for careful analysis of noncoding regions in patients with a T-B+NK- SCID phenotype in which no <em>IL2RG</em> or <em>JAK3</em> exonic or canonical splice-site pathogenic variants have been identified [<a href="#rid60">60</a>]. Moreover, synonymous exonic pathogenic variants that create novel cryptic splice sites may also cause JAK3 deficiency [<a href="#rid61">61</a>]. In such cases, sequencing of the complementary deoxyribonucleic acid (cDNA) product may facilitate the diagnosis. Identification of the specific gene pathogenic variants in the patient and confirmation of asymptomatic <em>JAK3</em> variant carrier status in the parents by sequencing allows for definitive diagnosis, as well as genetic counseling and prenatal diagnosis for management of future pregnancies [<a href="#rid62">62</a>].</p><p>JAK3 deficiency is compatible with the presence of significant numbers of circulating, although mostly poorly functioning, T cells [<a href="#rid47">47,51,63</a>]. Thus, screening for <em>JAK3</em> expression and/or pathogenic variants should not be limited to T cell lymphopenic patients. Such screening should also be considered in all undefined cases of combined immunodeficiency, especially those presenting with high proportions of peripheral B cells.</p><p class="headingAnchor" id="H4141741"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of SCID is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview", section on 'Differential diagnosis'</a>.)</p><p>The clinical and immunologic phenotype of JAK3 deficiency has features similar to X-linked severe combined immunodeficiency (X-SCID) [<a href="#rid64">64</a>]. If natural killer (NK) cells are present to some degree, it can be confused with interleukin 7 receptor alpha (IL-7R-alpha) deficiency, which is typically a T-B+NK+ SCID [<a href="#rid34">34</a>]. Features that can help distinguish JAK3 deficiency from other forms of SCID include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Parental consanguinity and presentation in female subjects can distinguish JAK3 deficiency from X-SCID [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence or very low numbers of NK cells in patients with JAK3 deficiency (with the exception of some patients with atypical JAK3 deficiency [<a href="#rid31">31</a>]) can aid the differential diagnosis with IL-7R-alpha deficiency, with the latter being compatible with NK cell development [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Molecular diagnosis can be made by sequencing a panel of SCID genes or by whole exome sequencing using next-generation sequencing methodology. Gene panels may focus on genes encoding proteins that have been found defective in T-B+ SCID (including CD3 delta, epsilon, and zeta chains; CD45; IL2RG; IL-2R-alpha chain; IL-7R-alpha; JAK3; and coronin-1A) or a comprehensive panel of SCID T-B+ and T-B- SCID genes (with addition to the above of adenylate kinase 2 associated with reticular dysgenesis; adenosine deaminase [ADA]; DNA crosslinked repair enzyme 1C or Artemis; ligase 4, nonhomologous end-joining protein 1, or Cernunnos; DNA-dependent protein kinase; Ras-related C3 botulinum toxin substrate 2 [RAC2]; and recombinase-activating genes 1 and 2)  (<a class="graphic graphic_table graphicRef139920" href="/z/d/graphic/139920.html" rel="external">table 1</a>). These methods are becoming more widely used as costs and turnaround time for whole exome sequencing decrease.</p><p></p><p class="headingAnchor" id="H7"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>A general overview of the management of SCID, including precautions that are undertaken prior to therapy while the definitive diagnosis is being determined, is discussed separately. The treatment of choice for SCID due to JAK3 deficiency is hematopoietic cell transplantation (HCT). Gene therapy is under investigation. HCT (including preferred donor source and complications after HCT) and gene therapy are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview", section on 'Protective measures'</a> and  <a class="medical medical_review" href="/z/d/html/3948.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Overview of management"</a> and  <a class="medical medical_review" href="/z/d/html/115988.html" rel="external">"Hematopoietic cell transplantation for severe combined immunodeficiencies"</a> and  <a class="medical medical_review" href="/z/d/html/3938.html" rel="external">"Overview of gene therapy for inborn errors of immunity"</a>.)</p><p>While awaiting determination of the optimal donor for HCT, it is essential that patients are maintained free from infections that could compromise their health status and ultimately the outcome of transplantation. If possible, reverse isolation should be used to protect these patients from environmental pathogens. It is imperative to provide protective <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> infusions and prophylactic antimicrobials to minimize the chance of <em>Pneumocystis jirovecii</em> pneumonia and other infections by bacterial, viral, and other fungal pathogens. (See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview", section on 'Protective measures'</a>.)</p><p class="headingAnchor" id="H4141872"><span class="h2">Hematopoietic cell transplantation</span><span class="headingEndMark"> — </span>No extensive data series are available on the specific results of HCT in JAK3-deficient patients because of the rarity of the disease. (See  <a class="medical medical_review" href="/z/d/html/115988.html" rel="external">"Hematopoietic cell transplantation for severe combined immunodeficiencies"</a>.)</p><p>A small series of 10 patients with JAK3 deficiency received HCT at a single institution [<a href="#rid3">3</a>]. Transplantation was from a human leukocyte antigen (HLA) identical family donor in two cases, from an unrelated cord blood in one case, and from a haploidentical parent in seven cases. Pre-HCT chemotherapy was used only in the patient who received cord blood transplantation. Nine of the 10 patients had attained robust T cell reconstitution and were reported to be alive and no longer prone to recurrent or opportunistic infections between 4 and 18 years after HCT. However, only three patients were able to discontinue treatment with intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a>, and donor B cell engraftment was achieved only in the child who received pre-HCT conditioning. In addition, seven of the nine patients continued to have poor natural killer (NK) cell numbers and/or function.</p><p>Generally, JAK3 deficiency has been grouped with other forms of T-B+ SCID (ie, X-linked severe combined immunodeficiency [X-SCID] and interleukin 7 receptor alpha [IL-7R-alpha] deficiency) in studies of HCT outcomes including larger series of patients. In a European series, for example, 10-year survival after HCT was 70 percent for 345 patients with T-B+ SCID [<a href="#rid65">65</a>]. Results from a single-center study were similar, with a survival rate of 72 percent (43 patients) 15 years after HCT [<a href="#rid66">66</a>]. In addition, a retrospective analysis of 662 patients with SCID who received HCT between 1982 and 2012 in North America found that overall survival was approximately 80 percent in the 211 followed with JAK3 deficiency or X-SCID, which was significantly better than that seen in patients affected with adenosine deaminase (ADA)<em> </em>or<em> </em>Artemis<em> </em>deficiency [<a href="#rid67">67</a>]. Early age (&lt;3.5 months of life) and lack of active infections at the time of transplantation are associated with improved outcome after haploidentical HCT in patients with X-SCID and JAK3 deficiency [<a href="#rid67">67</a>].</p><p>Successful reconstitution of T cell numbers and function can be obtained after transplantation of bone marrow-derived hematopoietic progenitors obtained from HLA-identical siblings; matched, unrelated volunteer donors; and haploidentical parents [<a href="#rid36">36,47,68-70</a>]. The lack of NK cells (and NK cell function) in JAK3-deficient patients makes graft rejection improbable, thereby facilitating the success of HCT. In addition, the early block in thymic T cell development that is characteristic of JAK3 deficiency probably favors thymic repopulation by the donor's normal lymphoid precursors and their differentiation into mature T cells.</p><p>The situation is quite different with regards to the reconstitution of the humoral immune response. Differentiation proceeds up to mature B cells in patients with JAK3 deficiency. The presence of these B cells, although functionally deficient, and that of their progenitors creates competition between autologous- and donor-derived B lymphopoiesis following HCT. Thus, the reconstitution of humoral immunity following haploidentical HCT is often incomplete, leading to the need of long-term administration of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> infusions [<a href="#rid3">3,36,69</a>]. Development of effective B cell function is more common following HCT from HLA-identical sibling donors and in patients receiving reduced-intensity or myeloablative conditioning [<a href="#rid66">66,67</a>]; it also has been observed even in some patients who maintained autologous B cells following HCT [<a href="#rid36">36,43,69</a>]. Reconstitution of NK function also seems unpredictable in patients with JAK3 deficiency [<a href="#rid3">3</a>].</p><p>An important complication of HCT in patients with SCID due to JAK3 deficiency is the appearance of warts due to papillomavirus infection even several years after transplant [<a href="#rid71">71</a>]. This long-term complication has been observed particularly in patients with X-SCID or JAK3 deficiency and less often in patients with SCID due to other genetic causes, suggesting that warts reflect an incomplete correction of defective gamma-c-mediated signaling defect in particular cell types, such as keratinocytes. However, the possible contribution of incomplete or vanishing immune reconstitution cannot be formally excluded.</p><p>Altogether, these results clearly indicate that HCT is a lifesaving procedure for SCID due to JAK3 deficiency [<a href="#rid3">3</a>]. However, in the absence of an HLA-identical family donor, the procedure is imperfect and leaves room for improvement.</p><p class="headingAnchor" id="H4141879"><span class="h2">Gene therapy</span><span class="headingEndMark"> — </span>Because of the phenotypic and biologic similarities between JAK3 deficiency and X-SCID and in light of the success of gene therapy in a series X-SCID patients, it is arguable that genetic correction of JAK3 deficiency may also result in clinical benefit [<a href="#rid72">72,73</a>]. On the other hand, one potential concern of using a "gene addition" approach is that the expression of the transferred gene is evicted from the cellular mechanisms of regulation and is constitutively expressed under the control of strong viral promoters. JAK3 has an important role in cell proliferation [<a href="#rid24">24,37</a>], and deregulated JAK3 expression could potentially result in uncontrolled cell division causing malignancy. (See  <a class="medical medical_review" href="/z/d/html/3938.html" rel="external">"Overview of gene therapy for inborn errors of immunity"</a>.)</p><p>Preclinical experiments in vitro [<a href="#rid37">37,38</a>] and in vivo [<a href="#rid74">74-76</a>] have illustrated the potential of gene therapy for JAK3 deficiency. Retroviral-mediated <em>JAK3</em> gene transfer was able to correct the biologic abnormalities of JAK3-deficient human B cell lines leading to reconstitution of IL-2 signaling (as assessed by IL-2-induced phosphorylation of JAK3 and signal transducer and activator of transcription 5 [STAT5]) and IL-2-mediated cell proliferation [<a href="#rid37">37,38</a>].</p><p>A series of in vivo experiments were performed and showed that ex-vivo retroviral-mediated <em>JAK3</em> gene transfer into hematopoietic progenitors from JAK3 knockout mice was able to restore specific T and B cell functions in mice transplanted with gene-corrected cells. Treated mice developed T cells able to respond to mitogens and develop specific cytotoxic responses. In addition, good reconstitution of humoral immunity was achieved following the procedure, with increased numbers of B cells and antibody production. More importantly, the same mice showed generation of specific antibody responses upon immunization and improved survival after exposure to influenza virus infection [<a href="#rid74">74,75</a>].</p><p>Another crucial finding of these experiments was that myeloablation was not necessary for the achievement of these significant improvements [<a href="#rid76">76</a>]. The strong selective advantage of JAK3-corrected lymphoid cells over unmodified autologous counterparts is probably responsible for these results that suggest that preparative conditioning is needed in the case of <em>JAK3</em> gene therapy protocols in humans.</p><p>A single JAK3-deficient patient who had failed HCT was enrolled in a gene therapy trial. The results of that experience were only published in abstract form and showed no evidence of immune reconstitution at seven months posttreatment [<a href="#rid77">77</a>]. This trial was placed on clinical hold, and no additional patients were enrolled because of the occurrence of leukemia in two children treated with gene therapy for X-SCID [<a href="#rid78">78</a>]. It is reasonable to assume that expression of JAK3 could have similar consequences. For these reasons, the US Food and Drug Administration (FDA) Biological Response Modifiers Advisory Committee made the recommendation in 2003 that, until more information is acquired, gene therapy for X-SCID and JAK3-SCID should be performed only on patients for whom alternative therapies are not available or have already failed. More recent developments in gene therapy for SCID include the use of self-inactivating vectors or lentivirus vectors that have been shown to be safer than the original constructs used for X-SCID gene therapy.</p><p>In addition, the ultimate goal of gene therapy (ie, the correction of the genetic defect within its genomic contest) is becoming a close reality thanks to the technologies of gene editing. Among these, a CRISPR/Cas9-based approach has been used to achieve the homology-directed repair of a pathogenic C1837T nonsense pathogenic variant of the <em>JAK3</em> gene in induced pluripotent stem cells (iPSCs) derived from a patient with JAK3 deficiency. In vitro differentiation experiments showed that, contrary to the original, mutated cells, the corrected iPSCs were able to generate T and NK cells. This demonstrates that lymphoid differentiation capability was restored, opening the way to the future development of this technology for gene therapy of patients affected with SCID due to JAK3 deficiency [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H4141909"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Affected patients typically die within the first year or two of life unless the underlying defect is corrected (see <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/z/d/html/115988.html" rel="external">"Hematopoietic cell transplantation for severe combined immunodeficiencies"</a> and  <a class="medical medical_review" href="/z/d/html/3938.html" rel="external">"Overview of gene therapy for inborn errors of immunity"</a>). More research is needed on very long-term outcomes to determine the best methods for hematopoietic cell transplantation (HCT) and/or gene therapy.</p><p class="headingAnchor" id="H4208960321"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a>.)</p><p class="headingAnchor" id="H2757112"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – Defects of the Janus kinase 3 (<em>JAK3</em>) gene result in a type of T cell-negative, B cell-positive, natural killer (NK) cell-negative severe combined immunodeficiency (T-B+NK- SCID) that is transmitted via an autosomal recessive mode of inheritance (MIM #600802). (See <a class="local">'Introduction'</a> above and <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – JAK3 is expressed in hematopoietic cells and is required for signal transduction of several cytokines. It is essential for lymphoid cell development. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Newborn screening and clinical presentation</strong> – Patients with SCID due to JAK3 deficiency are readily identified by SCID newborn screening because of their failure to generate mature T cells in the thymus. In locales where SCID newborn screening is not performed, affected infants present at a few months of age with the infectious complications that comprise the classical clinical features of SCID, including recurrent or severe respiratory infections, intractable diarrhea, thrush, and failure to thrive. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis and differential</strong> – Definitive diagnosis requires demonstration of deleterious homozygous or compound heterozygous pathogenic variants of the <em>JAK3</em> gene and/or biochemical evidence of impairment of JAK3 expression and/or function in patient lymphocytes. The clinical and immunologic phenotype of JAK3 deficiency has features distinct from X-linked SCID (X-SCID) and interleukin 7 receptor alpha (IL-7R-alpha) deficiency. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– The treatment of choice for SCID due to JAK3 deficiency is hematopoietic cell transplantation (HCT). Gene therapy is under investigation. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/z/d/html/115988.html" rel="external">"Hematopoietic cell transplantation for severe combined immunodeficiencies"</a> and  <a class="medical medical_review" href="/z/d/html/3938.html" rel="external">"Overview of gene therapy for inborn errors of immunity"</a>.)</p><p></p><p class="headingAnchor" id="H950441710"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995; 377:65.</a></li><li><a class="nounderline abstract_t">Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995; 270:797.</a></li><li><a class="nounderline abstract_t">Roberts JL, Lengi A, Brown SM, et al. Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. Blood 2004; 103:2009.</a></li><li><a class="nounderline abstract_t">Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA 2014; 312:729.</a></li><li><a class="nounderline abstract_t">Khanolkar A, Wilks JD, Liu G, et al. A case of aberrant CD8 T cell-restricted IL-7 signaling with a Janus kinase 3 defect-associated atypical severe combined immunodeficiency. Immunol Res 2020; 68:13.</a></li><li><a class="nounderline abstract_t">Candotti F, Oakes SA, Johnston JA, et al. Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood 1997; 90:3996.</a></li><li><a class="nounderline abstract_t">Mella P, Schumacher RF, Cranston T, et al. Eleven novel JAK3 mutations in patients with severe combined immunodeficiency-including the first patients with mutations in the kinase domain. Hum Mutat 2001; 18:355.</a></li><li><a class="nounderline abstract_t">Buckley RH, Schiff RI, Schiff SE, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 1997; 130:378.</a></li><li><a class="nounderline abstract_t">Lesmana H, Popescu M, Lewis S, et al. Germline gain-of-function JAK3 mutation in familial chronic lymphoproliferative disorder of NK cells. Blood 2020; 136, Suppl 1:9.</a></li><li><a class="nounderline abstract_t">Pai SY, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med 2014; 371:434.</a></li><li><a class="nounderline abstract_t">Dvorak CC, Haddad E, Buckley RH, et al. The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). J Allergy Clin Immunol 2019; 143:405.</a></li><li><a class="nounderline abstract_t">Vihinen M, Arredondo-Vega FX, Casanova JL, et al. Primary immunodeficiency mutation databases. Adv Genet 2001; 43:103.</a></li><li><a class="nounderline abstract_t">O'Shea JJ, Notarangelo LD, Johnston JA, Candotti F. Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency. J Clin Immunol 1997; 17:431.</a></li><li><a class="nounderline abstract_t">Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000; 408:57.</a></li><li><a class="nounderline abstract_t">Takeshita T, Asao H, Ohtani K, et al. Cloning of the gamma chain of the human IL-2 receptor. Science 1992; 257:379.</a></li><li><a class="nounderline abstract_t">Kondo M, Takeshita T, Ishii N, et al. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science 1993; 262:1874.</a></li><li><a class="nounderline abstract_t">Russell SM, Keegan AD, Harada N, et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science 1993; 262:1880.</a></li><li><a class="nounderline abstract_t">Noguchi M, Nakamura Y, Russell SM, et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science 1993; 262:1877.</a></li><li><a class="nounderline abstract_t">Kondo M, Takeshita T, Higuchi M, et al. Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes. Science 1994; 263:1453.</a></li><li><a class="nounderline abstract_t">Russell SM, Johnston JA, Noguchi M, et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 1994; 266:1042.</a></li><li><a class="nounderline abstract_t">Kimura Y, Takeshita T, Kondo M, et al. Sharing of the IL-2 receptor gamma chain with the functional IL-9 receptor complex. Int Immunol 1995; 7:115.</a></li><li><a class="nounderline abstract_t">Giri JG, Ahdieh M, Eisenman J, et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 1994; 13:2822.</a></li><li><a class="nounderline abstract_t">Asao H, Okuyama C, Kumaki S, et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001; 167:1.</a></li><li><a class="nounderline abstract_t">Miyazaki T, Kawahara A, Fujii H, et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 1994; 266:1045.</a></li><li><a class="nounderline abstract_t">Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993; 73:147.</a></li><li><a class="nounderline abstract_t">Puck JM, Deschênes SM, Porter JC, et al. The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. Hum Mol Genet 1993; 2:1099.</a></li><li><a class="nounderline abstract_t">Vély F, Barlogis V, Vallentin B, et al. Evidence of innate lymphoid cell redundancy in humans. Nat Immunol 2016; 17:1291.</a></li><li><a class="nounderline abstract_t">Robinette ML, Cella M, Telliez JB, et al. Jak3 deficiency blocks innate lymphoid cell development. Mucosal Immunol 2018; 11:50.</a></li><li><a class="nounderline abstract_t">Basheer F, Lee E, Liongue C, Ward AC. Zebrafish Model of Severe Combined Immunodeficiency (SCID) Due to JAK3 Mutation. Biomolecules 2022; 12.</a></li><li><a class="nounderline abstract_t">Lodolce JP, Boone DL, Chai S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998; 9:669.</a></li><li><a class="nounderline abstract_t">Li J, Nara H, Rahman M, et al. Impaired IL-7 signaling may explain a case of atypical JAK3-SCID. Cytokine 2010; 49:221.</a></li><li><a class="nounderline abstract_t">von Freeden-Jeffry U, Vieira P, Lucian LA, et al. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 1995; 181:1519.</a></li><li><a class="nounderline abstract_t">Peschon JJ, Morrissey PJ, Grabstein KH, et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994; 180:1955.</a></li><li><a class="nounderline abstract_t">Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet 1998; 20:394.</a></li><li><a class="nounderline abstract_t">Chang CW, Lai YS, Westin E, et al. Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene Targeting. Cell Rep 2015; 12:1668.</a></li><li><a class="nounderline abstract_t">Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999; 340:508.</a></li><li><a class="nounderline abstract_t">Candotti F, Oakes SA, Johnston JA, et al. In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction. J Exp Med 1996; 183:2687.</a></li><li><a class="nounderline abstract_t">Oakes SA, Candotti F, Johnston JA, et al. Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways. Immunity 1996; 5:605.</a></li><li><a class="nounderline abstract_t">Zotos D, Coquet JM, Zhang Y, et al. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med 2010; 207:365.</a></li><li><a class="nounderline abstract_t">Linterman MA, Beaton L, Yu D, et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med 2010; 207:353.</a></li><li><a class="nounderline abstract_t">Recher M, Berglund LJ, Avery DT, et al. IL-21 is the primary common γ chain-binding cytokine required for human B-cell differentiation in vivo. Blood 2011; 118:6824.</a></li><li><a class="nounderline abstract_t">Miggelbrink AM, Logan BR, Buckley RH, et al. B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. Blood 2018; 131:2967.</a></li><li><a class="nounderline abstract_t">Bozzi F, Lefranc G, Villa A, et al. Molecular and biochemical characterization of JAK3 deficiency in a patient with severe combined immunodeficiency over 20 years after bone marrow transplantation: implications for treatment. Br J Haematol 1998; 102:1363.</a></li><li><a class="nounderline abstract_t">Riedy MC, Dutra AS, Blake TB, et al. Genomic sequence, organization, and chromosomal localization of human JAK3. Genomics 1996; 37:57.</a></li><li><a class="nounderline abstract_t">Schumacher RF, Mella P, Badolato R, et al. Complete genomic organization of the human JAK3 gene and mutation analysis in severe combined immunodeficiency by single-strand conformation polymorphism. Hum Genet 2000; 106:73.</a></li><li><a class="nounderline abstract_t">Kawamura M, McVicar DW, Johnston JA, et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci U S A 1994; 91:6374.</a></li><li><a class="nounderline abstract_t">Notarangelo LD, Mella P, Jones A, et al. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency. Hum Mutat 2001; 18:255.</a></li><li><a class="nounderline abstract_t">Di Matteo G, Chiriaco M, Scarselli A, et al. JAK3 mutations in Italian patients affected by SCID: New molecular aspects of a long-known gene. Mol Genet Genomic Med 2018; 6:713.</a></li><li><a class="nounderline abstract_t">Cacalano NA, Migone TS, Bazan F, et al. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain. EMBO J 1999; 18:1549.</a></li><li><a class="nounderline abstract_t">Chen M, Cheng A, Candotti F, et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol 2000; 20:947.</a></li><li><a class="nounderline abstract_t">Frucht DM, Gadina M, Jagadeesh GJ, et al. Unexpected and variable phenotypes in a family with JAK3 deficiency. Genes Immun 2001; 2:422.</a></li><li><a class="nounderline abstract_t">Sato T, Okano T, Tanaka-Kubota M, et al. Novel compound heterozygous mutations in a Japanese girl with Janus kinase 3 deficiency. Pediatr Int 2016; 58:1076.</a></li><li class="breakAll">US Centers for Disease Control and Prevention: Rotavirus Vaccine Information Statement. http://www.cdc.gov/vaccines/hcp/vis/vis-statements/rotavirus.html.</li><li><a class="nounderline abstract_t">Ban SA, Salzer E, Eibl MM, et al. Combined immunodeficiency evolving into predominant CD4+ lymphopenia caused by somatic chimerism in JAK3. J Clin Immunol 2014; 34:941.</a></li><li><a class="nounderline abstract_t">Scarselli A, Di Cesare S, Di Matteo G, et al. Combined immunodeficiency due to JAK3 mutation in a child presenting with skin granuloma. J Allergy Clin Immunol 2016; 137:948.</a></li><li><a class="nounderline abstract_t">Leclerc-Mercier S, Moshous D, Neven B, et al. Cutaneous granulomas with primary immunodeficiency in children: a report of 17 new patients and a review of the literature. J Eur Acad Dermatol Venereol 2019; 33:1412.</a></li><li><a class="nounderline abstract_t">Perelygina L, Icenogle J, Sullivan KE. Rubella virus-associated chronic inflammation in primary immunodeficiency diseases. Curr Opin Allergy Clin Immunol 2020; 20:574.</a></li><li><a class="nounderline abstract_t">Zhong L, Wang W, Ma M, et al. Chronic active Epstein-Barr virus infection as the initial symptom in a Janus kinase 3 deficiency child: Case report and literature review. Medicine (Baltimore) 2017; 96:e7989.</a></li><li><a class="nounderline abstract_t">Hale JE, Bonilla FA, Pai SY, et al. Identification of an infant with severe combined immunodeficiency by newborn screening. J Allergy Clin Immunol 2010; 126:1073.</a></li><li><a class="nounderline abstract_t">Stepensky P, Keller B, Shamriz O, et al. Deep intronic mis-splicing mutation in JAK3 gene underlies T-B+NK- severe combined immunodeficiency phenotype. Clin Immunol 2016; 163:91.</a></li><li><a class="nounderline abstract_t">Platt CD, Massaad MJ, Cangemi B, et al. Janus kinase 3 deficiency caused by a homozygous synonymous exonic mutation that creates a dominant splice site. J Allergy Clin Immunol 2017; 140:268.</a></li><li><a class="nounderline abstract_t">Schumacher RF, Mella P, Lalatta F, et al. Prenatal diagnosis of JAK3 deficient SCID. Prenat Diagn 1999; 19:653.</a></li><li><a class="nounderline abstract_t">Brugnoni D, Notarangelo LD, Sottini A, et al. Development of autologous, oligoclonal, poorly functioning T lymphocytes in a patient with autosomal recessive severe combined immunodeficiency caused by defects of the Jak3 tyrosine kinase. Blood 1998; 91:949.</a></li><li><a class="nounderline abstract_t">Puck JM, Pepper AE, Henthorn PS, et al. Mutation analysis of IL2RG in human X-linked severe combined immunodeficiency. Blood 1997; 89:1968.</a></li><li><a class="nounderline abstract_t">Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 2010; 126:602.</a></li><li><a class="nounderline abstract_t">Abd Hamid IJ, Slatter MA, McKendrick F, et al. Long-term outcome of hematopoietic stem cell transplantation for IL2RG/JAK3 SCID: a cohort report. Blood 2017; 129:2198.</a></li><li><a class="nounderline abstract_t">Haddad E, Logan BR, Griffith LM, et al. SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood 2018; 132:1737.</a></li><li><a class="nounderline abstract_t">Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000; 343:1313.</a></li><li><a class="nounderline abstract_t">Haddad E, Landais P, Friedrich W, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 1998; 91:3646.</a></li><li><a class="nounderline abstract_t">Bertrand Y, Landais P, Friedrich W, et al. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European group for bone marrow transplantation and the european society for immunodeficiency. J Pediatr 1999; 134:740.</a></li><li><a class="nounderline abstract_t">Laffort C, Le Deist F, Favre M, et al. Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency. Lancet 2004; 363:2051.</a></li><li><a class="nounderline abstract_t">Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288:669.</a></li><li><a class="nounderline abstract_t">Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346:1185.</a></li><li><a class="nounderline abstract_t">Bunting KD, Sangster MY, Ihle JN, Sorrentino BP. Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer. Nat Med 1998; 4:58.</a></li><li><a class="nounderline abstract_t">Bunting KD, Flynn KJ, Riberdy JM, et al. Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency. Proc Natl Acad Sci U S A 1999; 96:232.</a></li><li><a class="nounderline abstract_t">Bunting KD, Lu T, Kelly PF, Sorrentino BP. Self-selection by genetically modified committed lymphocyte precursors reverses the phenotype of JAK3-deficient mice without myeloablation. Hum Gene Ther 2000; 11:2353.</a></li><li><a class="nounderline abstract_t">Sorrentino BP, Lu T, Ihle J. A clinical attempt to treat JAK3-deficient SCID using retroviral-mediated gene transfer to bone marrow CD34+ cells. Molecular Therapy 2003; 7:S449.</a></li><li><a class="nounderline abstract_t">"The Pink Sheet". Gene therapy trial clinical hold will be topic of FDA, NIH meetings. January 20, 2003; 65:7.</a></li></ol></div><div id="topicVersionRevision">Topic 3961 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7659163" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7481768" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14615376" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25138334" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32215810" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A case of aberrant CD8 T cell-restricted IL-7 signaling with a Janus kinase 3 defect-associated atypical severe combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9354668" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Structural and functional basis for JAK3-deficient severe combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11668621" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Eleven novel JAK3 mutations in patients with severe combined immunodeficiency-including the first patients with mutations in the kinase domain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9063412" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Germline gain-of-function JAK3 mutation in familial chronic lymphoproliferative disorder of NK cells</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25075835" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Transplantation outcomes for severe combined immunodeficiency, 2000-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30193840" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11037300" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Primary immunodeficiency mutation databases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9418183" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11081504" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1631559" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cloning of the gamma chain of the human IL-2 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8266076" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8266078" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8266077" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8128231" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7973658" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7718508" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sharing of the IL-2 receptor gamma chain with the functional IL-9 receptor complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8026467" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11418623" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7973659" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8462096" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8401490" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27618553" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Evidence of innate lymphoid cell redundancy in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28513593" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Jak3 deficiency blocks innate lymphoid cell development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36291730" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Zebrafish Model of Severe Combined Immunodeficiency (SCID) Due to JAK3 Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9846488" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19889552" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Impaired IL-7 signaling may explain a case of atypical JAK3-SCID.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7699333" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7964471" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9843216" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26321643" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene Targeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10021471" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8676091" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8986719" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20142430" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20142429" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22039266" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : IL-21 is the primary commonγchain-binding cytokine required for human B-cell differentiation in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29728406" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9753072" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Molecular and biochemical characterization of JAK3 deficiency in a patient with severe combined immunodeficiency over 20 years after bone marrow transplantation: implications for treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8921370" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Genomic sequence, organization, and chromosomal localization of human JAK3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10982185" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Complete genomic organization of the human JAK3 gene and mutation analysis in severe combined immunodeficiency by single-strand conformation polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8022790" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11668610" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30032486" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : JAK3 mutations in Italian patients affected by SCID: New molecular aspects of a long-known gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10075926" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10629052" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11781709" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Unexpected and variable phenotypes in a family with JAK3 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27593409" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Novel compound heterozygous mutations in a Japanese girl with Janus kinase 3 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27593409" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Novel compound heterozygous mutations in a Japanese girl with Janus kinase 3 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25205547" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Combined immunodeficiency evolving into predominant CD4+ lymphopenia caused by somatic chimerism in JAK3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26545580" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Combined immunodeficiency due to JAK3 mutation in a child presenting with skin granuloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30869812" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cutaneous granulomas with primary immunodeficiency in children: a report of 17 new patients and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33044342" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Rubella virus-associated chronic inflammation in primary immunodeficiency diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29049190" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Chronic active Epstein-Barr virus infection as the initial symptom in a Janus kinase 3 deficiency child: Case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20933257" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Identification of an infant with severe combined immunodeficiency by newborn screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26769277" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Deep intronic mis-splicing mutation in JAK3 gene underlies T-B+NK- severe combined immunodeficiency phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27956217" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Janus kinase 3 deficiency caused by a homozygous synonymous exonic mutation that creates a dominant splice site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10419614" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prenatal diagnosis of JAK3 deficient SCID.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9446656" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Development of autologous, oligoclonal, poorly functioning T lymphocytes in a patient with autosomal recessive severe combined immunodeficiency caused by defects of the Jak3 tyrosine kinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9058718" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Mutation analysis of IL2RG in human X-linked severe combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20673987" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28209722" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Long-term outcome of hematopoietic stem cell transplantation for IL2RG/JAK3 SCID: a cohort report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30154114" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11058677" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Primary immunodeficiency diseases due to defects in lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9573000" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10356144" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European group for bone marrow transplantation and the european society for immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15207958" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10784449" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11961146" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9427607" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9874801" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11096440" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Self-selection by genetically modified committed lymphocyte precursors reverses the phenotype of JAK3-deficient mice without myeloablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A clinical attempt to treat JAK3-deficient SCID using retroviral-mediated gene transfer to bone marrow CD34+ cells</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Gene therapy trial clinical hold will be topic of FDA, NIH meetings</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
